Adaptimmune治療公共 ADAP 深 滬
已收盤 08-08 16:00:00 美东时间
0.0775
-0.005
-6.63%
華盛通- 最 高0.083
- 今 開0.083
- 成交量 2670.94万股
- 最 低 0.0745
- 昨 收 0.083
- 總市值 2053.75万
- 52周最高 1.33
- 市盈率 靜 --
- 換手率 10.08%
- 52周最低 0.071
- 委 比 -95.15%
- 總股本 2.65亿
- 歷史最高 21.57
- 量 比 0.19
- 振 幅 10.24%
- 歷史最低 0.071
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Y-mAbs Therapeutics (NASDAQ:YMAB) stock rose 103.2% to $8.52 during Tu...
08-06 01:06
Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of Palantir Technologies Inc. (NASDAQ:PLTR) rose sharply in pre-market t...
08-05 17:50
制药巨头扎堆做“减法”：20家药企7月宣布裁员
2025 年已经过半，裁员、削减成本，成为众多药企不得不面对的现实。据 Fierce Biotech 统计，仅在今年 7 月，就有 20 家药企宣布了裁员计划...
08-01 12:49
Vivakor Confirms Special Dividend of Adapti, Inc. Record Date Set for August 20, 2025
Vivakor, Inc. announced a record date of August 20, 2025, for a special dividend to shareholders. The dividend will be in the form of Adapti, Inc. common stock, with each Vivakor shareholder receiving approximately 0.0079 shares of Adapti based on the current stock price of $3.50, valuing the dividend at approximately $0.75 million. Vivakor currently holds 13.5% of Adapti's outstanding shares. Adapti recently completed its SEC registration and fi...
07-31 12:30
阿斯利康撤回三款产品，药企集体进入“冷静期”？
（来源：动脉新医药） 7月29日，阿斯利康发布了2025年半年财报，其上半年总收入达280.45亿美元，增长11%。药品营业收入达到267.7亿美元，增长主要来...
07-31 08:02
HC Wainwright & Co. Downgrades Adaptimmune Therapeutics to Neutral
HC Wainwright & Co. analyst Arthur He downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) from Buy to Neutral.
07-29 19:47
H.C. Wainwright downgrades Adaptimmune Therapeutics (ADAP) to a Hold
Adaptimmune Therapeutics received a Hold rating and price target from H.C. Wain...
07-29 18:17
Adaptimmune Sells Cell Therapy Assets to US WorldMeds
The latest announcement is out from Adaptimmune Therapeutics ( ($ADAP) ). On Ju...
07-28 19:58
Adaptimmune Therapeutics Agreed To Sell Tecelra, Lete-cel, Afami-cel, And Uza-cel Cell Therapies To US WorldMeds For $55M And Milestone Payment Of Up To $30M
Under the terms of the asset purchase agreement, US WorldMeds will purchase the TECELRA, uza-cel, afami-cel and lete-cel cell therapy assets of Adaptimmune (the "Assigned Assets") and all intellectual property rights
07-28 19:35
多面手OX40：炎症、自免、肿瘤治疗新希望
（来源：药研网） 前言 2025年7月2日，创响生物宣布，抗OX40单抗IMG-007在中重度特应性皮炎（AD）国际多中心IIb期研究（ADAPTIVE，NC...
07-23 07:50
